Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Dermatology

Journal Scan / Research · April 28, 2022

Risk Factors for Developing Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors

JAMA Dermatology

 

 Save  Recommend
 Share

Additional Info

JAMA Dermatology
Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors
JAMA Dermatol 2022 Apr 13;[EPub Ahead of Print], JT Said, M Liu, J Talia, SB Singer, YR Semenov, EX Wei, A Mostaghimi, CA Nelson, A Giobbie-Hurder, NR LeBoeuf

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated